Le Lézard
Classified in: Health
Subject: SVY

Breast Biopsy Market Expected to Reach $1,420 Million by 2023 - Allied Market Research



PORTLAND, Oregon and PUNE, India, October 6, 2017 /PRNewswire/ --

According to a new report published by Allied Market Research titled, Breast Biopsy Market by Product and End User - Global Opportunity Analysis and Industry Forecast, 2017-2023, the global breast biopsy market was valued at $977 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. Core needle biopsy (CNB) segment accounted for about half of the global market share in 2016.

A breast biopsy is the procedure of locating a diseased tissue in the breast and collecting the specimen sample of the area for further examination and diagnosis. Breast biopsies are performed by using minimally invasive biopsy systems, owing to minimal disfigurement and pain. Non-invasive biopsy techniques provide preventive measures that assist physicians in diagnosing and treating high-risk breast cancer. This information prevents the application of chemotherapy in breast cancer, reducing the complexities of chemo-radiations. Vacuum assisted breast biopsy devices (VAB), core needle biopsies and fine needle aspiration biopsy are commonly used to perform biopsy procedures.

Do Enquiry for Sample Report@ https://www.alliedmarketresearch.com/request-sample/1067

The major factors that boost the market growth include rise in incidence of breast cancer, growth in awareness toward cancer screening programs, and increase in demand for minimal invasive breast biopsies. Moreover, the ongoing technological advancements of diagnostic and treatment technology for breast cancer have undergone a gradual transition from open surgery to minimal invasive biopsy procedures. Breast cancer is the most common type of cancer in women, especially in the U.S., where it is the second leading cause of death propels the demand for breast biopsy procedures. Furthermore, requirement of robust measures for disease control, the thrust for newer technologies has led to the development of minimal invasive surgeries. This has made breast biopsy as preferred modality to diagnose breast cancer and identify complex tumors and make accurate diagnosis. However, lack of awareness toward the availability of novel breast biopsy techniques and risk of infection involved in the procedures are projected to hamper the market growth.

The core needle biopsy (CNB) segment dominated the global market in 2016, and is expected to maintain this trend throughout the analysis period, owing to the less invasive procedure compared to others and it provides more definitive diagnosis. Moreover, use of CNB and ultra sonographic and mammographic guidance is highly accurate for diagnosing breast cancer that supplements the market growth.

The ultrasound guided biopsy is poised to grow at the highest rate during the forecast period, owing to the sound waves used instead ionizing radiation to locate abnormality or lump and is less invasive in nature with reduced scars. Ultrasound guided biopsy segment is expected to grow at a high CAGR of 6.1% from 2017 to 2023.

Do Enquiry before purchasing Report@ https://www.alliedmarketresearch.com/purchase-enquiry/1067

Asia-Pacific is anticipated to grow at a highest rate throughout the analysis period, owing to the continuous growth in countries, such as Japan, India, China, and Australia. For instance, in Japanese women between the age group of 30-64, breast cancer is one of the leading cancer types over the past decade. In addition, as per Japanese Society of Breast Health, one in every 20 women are diagnosed with breast cancer in Japan. This is a clear trend toward the increase in demand for breast biopsy procedures for screening and diagnosis of breast cancer at early stages. Furthermore, commandment by the government bodies for routine screening for breast cancer after the age of 40 for women has raised the demand for breast biopsy devices. Technological advancements for cost-effective devices in these nations offer a lucrative opportunity for the breast biopsy market growth.

Key Findings of the Breast Biopsy Market:


Key players operating in the market include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

Ask for discount before buying@ https://www.alliedmarketresearch.com/get-discount/1067

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


Contact:
Dhananjay Potle
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: + 852-301-84916
India (Pune): +91-20-66346060
Fax : +1?855?550-5975
help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com  

SOURCE Allied Market Research


These press releases may also interest you

at 05:00
The Pancreatic Cancer Action Network (PanCAN) is proud to announce that Peter Cashion, MBA, has been elected to its Board of Directors. In his new leadership role in the fight against the world's toughest cancer, Cashion brings over 20 years'...

at 05:00
Novasep, a leading supplier of services and technologies for the life sciences industry, is proud to announce today that it has been selected by Tetraphase for the commercial manufacture of the active pharmaceutical ingredient (API) eravacycline, an...

at 04:30
The global contrast media injectors market is expected to reach USD 1.4 billion by 2025, growing at a CAGR of 5.8%, according to a new report by Grand View Research, Inc. Rising demand for minimally invasive surgical procedures is a major factor...

at 04:00
Today, Ascensia Diabetes Care has announced the launch of its upgraded version of the CONTOUR®DIABETES app in the United Kingdom and Ireland. It includes the new My Patterns feature, which can more intelligently analyse blood glucose results received...

at 03:00
Clearbridge BioMedics today announced that its ClearCell® FX1 System is now broadly available in EMEA and APAC regions to complement its direct availability in the US and existing distribution channels. This was made possible through partnerships...

at 03:00
Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced the appointment of Dr. Patricia Zilliox as CEO. Dr. Zilliox, who joined the Eyevensys board in May 2016, has more than 25 years...




News published on 6 october 2017 at 06:45 and distributed by: